Parkinson's disease: a brief overview and clinical observation
https://doi.org/10.24412/2790-1289-2024-2-66-72
Abstract
Parkinson's disease is the second most common neurodegenerative disease, and its prevalence is projected to double over the next generation. Nevertheless, timely diagnosis of Parkinson's disease remains
a difficult task, and the identification of the earliest stages of the disease is a serious unmet need. In this paper, we described a case of diagnosis of the classic form of Parkinson's disease in an elderly patient.
In this paper, we describe a clinical case of diagnosing the classic form of Parkinson's disease in an elderly patient with late diagnosis at the Department of Neurology at the Central City Clinical Hospital in
Almaty. Based on clinical and instrumental data, the diagnosis was established as: Parkinson's disease, akinetic-rigid form, without postural instability, Stage 4 according to the Hen and Yaru scale.
The presented clinical example demonstrates a classic case of Parkinson's disease. The gradual development of symptoms, along with the presence of typical motor and non-motor manifestations in an elderly patient, allowed for the clinical diagnosis of Parkinson's disease.
About the Authors
M. A. Karzhaubayeva
«Kazakh-Russian medical university» NEI
Kazakhstan
Kazakhstan
Karzhaubaeva Manchuk Amantaevna – senior lecturer at the Department of Neurology
Almaty
A. B. Sapargalieva
«Kazakh-Russian medical university» NEI
Kazakhstan
Kazakhstan
Sapargalieva Akmaral Bolatbekkyzy – resident neurologist 2nd year
Almaty
A. S. Rysbaeva
«Kazakh-Russian medical university» NEI
Kazakhstan
Kazakhstan
Rysbaeva Aidana Sagidullayevna – resident neurologist 2nd year
Almaty
References
1. Goldman, S. M, Tanner, C. (1998). Etiology of Parkinson's's disease. In: Jankovic, J., Tolosa, E., editors. Parkinson's's disease and movement disorders, 3rd ed. – Baltimore, MD: Lippincott-Williams and Wilkins, 133-158.
2. Schrag, A., Schott, J. M. (2006). Epidemiological, clinical, and genetic characteristics of early-onset Parkinsonism, The Lancet. Neurology, 5, 355-363.
3. Kalia, L. V., Lang, A. E. (2015). Parkinson’s disease. Lancet, 386(9996), 896-912, DOI: 10.1016/S0140-6736(14)61393-3.
4. Poewe, W., Seppi, K., Tanner, C. M. et al. (2017). Parkinson disease. Nature Reviews Disease Primers, 3, 17013, DOI: 10.1038/nrdp.2017.13.
5. Rajput, A. H., Rajput, A. (2014). Accuracy of Parkinson disease diagnosis unchanged in 2 decade. Neurology, 83(5), 386-387, DOI: 10.1212/WNL.0000000000000653.
6. Dorsey, E. R., Sherer, T., Okun, M. S., Bloem, B. R. (2018). The Emerging Evidence of the Parkinson Pandemic Journal of Parkinson's Disease, 8(s1), 3-8, DOI: 10.3233/JPD-181474.
7. Hughes, A. J., Daniel, S. E., Kilford, L., Lees, A. J. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson's disease. A clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery and Psychiatry, 55, 181-184.
8. Chaudhuri, K. R., Schapira, A. H. (2009). Nonmotor symptoms of Parkinson's's disease: Dopaminergic pathophysiology and treatment. Lancet Neurology, 8, 464-474.
9. Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M., Morris, J. G. (2008). The Sydney multicenter study of Parkinson's's disease: The inevitability of dementia at 20 years. Movement Disorders, 23, 837-844.
10. Rizzo, G., Copetti, M., Arcuti, S., Martino, D., Fontana, A., Logroscino, G. (2016). Accuracy of clinical diagnosis of Parkinson's disease: A systematic review and meta- analysis. Neurology, 86, 566-576.
11. Lehéricy, S., Sharman, M. A., Santos, CLD., Paquin, R., Gallea, C. (2012). Magnetic resonance imaging of the substantia nigra in Parkinson's's disease. Movement Disorders, 27, 822-830.
12. Mahlknecht, P., Hotter, A., Hussl, A., Esterhammer, R., Schocke, M., Seppi, K. (2010). Significance of MRI in diagnosis and differential diagnosis of Parkinson's disease. Neurodegenerative Diseases, 7, 300-318.
13. Treglia, G., Cason, E., Stefanelli, A., Cocciolillo, F., Di Giuda, D., Fagioli, G. et al. (2012). MIBG scintigraphy in differential diagnosis of Parkinsonism: A meta-analysis. Clinical Autonomic Research, 22, 43-55.
14. Chen-Plotkin, A. S. (2014). Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron, 84, 594-607.
15. Swanson, C. R., Berlyand, Y., Xie, S. X., Alcalay, R. N., Chahine, L. M., Chen-Plotkin, A. S. (2015). Plasma ApoA1 associates with age at onset and motor severity in early Parkinson's disease patients. Movement Disorders, 30, 1648-1656.
16. Schapira A. H. V. (2013). Recent developments in biomarkers in Parkinson's disease. Current Opinion in Neurology 26, 395-400.
17. LeWitt, P. A., Fahn, S. (2016). Levodopa therapy for Parkinson's disease: A look backward and forward. Neurology, 86, 3-12.
18. Katzenschlager, R., Hughes, A., Evans, A., Manson, A.J., Hoffman, M., Swinn, L. et al. (2005). Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single-dose challenges. Movement Disorders, 20, 151-157.
19. Pandey, S. (2016). When to do deep brain stimulation surgery in Parkinson disease? Early or late? Neurology India, 64, 8-9.
20. Zhou, Z. H., Wu, Y. F., Wang, X., Hahn, Y. Z. (2017). The c-Abl inhibitor in Parkinson's disease. Neurology Science, 38, 547-552.
Review
For citations:
Karzhaubayeva M.A., Sapargalieva A.B., Rysbaeva A.S. Parkinson's disease: a brief overview and clinical observation. Actual Problems of Theoretical and Clinical Medicine. 2024;(2):67-74. (In Russ.) https://doi.org/10.24412/2790-1289-2024-2-66-72
Views:
104
